Danish in-vitro diagnostics company, BioPorto, has entered an agreement with the German medico giant, Siemens Healthcare, on distribution of BioPorto’s NGAL Test, an effective biomarker test in the diagnosis of acute kidney injury. NGAL (neutrophil gelatinase-associated lipocalin) is a small protein expressed in the renal tubules. NGAL levels rise within two hours of the insult, making NGAL an early and sensitive biomarker of kidney injury.
The distribution agreement includes a version of the test adjusted to Siemens Healthcare’s BN II and BN ProSpec systems. The agreement between the two companies is exclusive with respect to the instruments and applies worldwide.
Additionally, Siemens Healthcare and BioPorto will collaborate on marketing of the adjusted test, and commercial sale of the NGAL Test will begin when the adjustment is completed.
Read more about BioPorto